Subtopic Deep Dive

Hypertrophic Cardiomyopathy Genetics
Research Guide

What is Hypertrophic Cardiomyopathy Genetics?

Hypertrophic Cardiomyopathy Genetics studies sarcomere gene mutations, especially in β-cardiac myosin heavy chain, causing left ventricular hypertrophy in HCM.

Research identifies mutations in 10+ genes with systematic screening in large cohorts (Richard et al., 2003, 1266 citations). Foundational work linked β-myosin heavy chain missense mutations to familial HCM (Geisterfer-Lowrance et al., 1990, 1376 citations). Guidelines recommend genetic testing for channelopathies and cardiomyopathies (Ackerman et al., 2011, 1448 citations). Over 20 key papers span 1990-2019.

15
Curated Papers
3
Key Challenges

Why It Matters

Genetic screening via sarcomere mutation panels enables familial HCM risk stratification, as detailed in ESC guidelines (Elliott et al., 2014, 4217 citations). Genotype-phenotype correlations from myosin heavy chain studies guide personalized management (Marian and Braunwald, 2017, 1265 citations). Seidman et al. (2001, 1041 citations) established genetic basis, supporting cascade screening in 50% autosomal dominant cases. Ackerman et al. (2011) consensus improved testing protocols, reducing sudden death risks in carriers.

Key Research Challenges

Incomplete Penetrance

Many sarcomere mutations show variable expressivity, complicating risk prediction (Richard et al., 2003). Modifier genes influence phenotype, as noted in myosin studies (Geisterfer-Lowrance et al., 1990). Genotype-phenotype mapping remains inconsistent across families.

Genotype-Phenotype Correlation

β-myosin heavy chain mutations vary in hypertrophy severity (Thierfelder et al., 1994, 1019 citations). Large cohort screening reveals no uniform patterns (Richard et al., 2003). Statistical models needed for precise correlations.

Genetic Testing Guidelines

Consensus varies on panel scope for HCM (Ackerman et al., 2011). Integration with ESC guidelines challenges clinical adoption (Elliott et al., 2014). Variant interpretation requires updated databases.

Essential Papers

1.

2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy

Perry Elliott, Aris Anastasakis, Michael A. Borger et al. · 2014 · European Heart Journal · 4.2K citations

NOT AVAILABLE

2.

HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies

Michael J. Ackerman, Silvia G. Priori, Stephan Willems et al. · 2011 · Heart Rhythm · 1.4K citations

3.

A molecular basis for familial hypertrophic cardiomyopathy: A β cardiac myosin heavy chain gene missense mutation

Anja A. T. Geisterfer-Lowrance, Susan Kass, G Tanigawa et al. · 1990 · Cell · 1.4K citations

4.

Hypertrophic Cardiomyopathy

Pascale Richard, Philippe Charron, Lucie Carrier et al. · 2003 · Circulation · 1.3K citations

Background— Hypertrophic cardiomyopathy is an autosomal-dominant disorder in which 10 genes and numerous mutations have been reported. The aim of the present study was to perform a systematic scree...

5.

The Genetic Basis for Cardiomyopathy

Jonathan G. Seidman, Christine E. Seidman · 2001 · Cell · 1.0K citations

6.

α-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere

Ludwig Thierfelder, Hugh Watkins, Calum A. MacRae et al. · 1994 · Cell · 1.0K citations

7.

HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA)

Michael J. Ackerman, Silvia G. Priori, Stephan Willems et al. · 2011 · EP Europace · 896 citations

PreambleThis international consensus statement provides the state of genetic testing for the channelopathies and cardiomyopathies.It summarizes the opinion of the international writing group member...

Reading Guide

Foundational Papers

Start with Geisterfer-Lowrance et al. (1990) for first myosin mutation discovery; Seidman and Seidman (2001) for genetic basis overview; Ackerman et al. (2011) for testing consensus.

Recent Advances

Marian and Braunwald (2017) reviews HCM genetics; Elliott et al. (2014) ESC guidelines integrate screening.

Core Methods

Cohort-based gene screening (Richard et al., 2003); linkage analysis for sarcomere proteins (Thierfelder et al., 1994); consensus-driven variant classification (Ackerman et al., 2011).

How PapersFlow Helps You Research Hypertrophic Cardiomyopathy Genetics

Discover & Search

Research Agent uses searchPapers and citationGraph to map sarcomere mutation literature from Geisterfer-Lowrance et al. (1990), revealing 1376 citing papers on myosin HCM genetics. exaSearch finds recent modifier gene studies; findSimilarPapers expands to Thierfelder et al. (1994) sarcomere networks.

Analyze & Verify

Analysis Agent applies readPaperContent to extract mutation frequencies from Richard et al. (2003), then runPythonAnalysis with pandas for penetrance statistics across cohorts. verifyResponse (CoVe) and GRADE grading verify claims like 50% autosomal dominance against Ackerman et al. (2011), flagging inconsistencies.

Synthesize & Write

Synthesis Agent detects gaps in modifier gene research post-Seidman et al. (2001); Writing Agent uses latexEditText, latexSyncCitations for Elliott et al. (2014), and latexCompile to generate genotype-phenotype review manuscripts. exportMermaid diagrams myosin mutation pathways.

Use Cases

"Analyze penetrance rates in β-myosin heavy chain mutations from HCM cohorts."

Research Agent → searchPapers('penetrance β-myosin HCM') → Analysis Agent → readPaperContent(Richard 2003) → runPythonAnalysis(pandas cohort stats) → GRADE-verified penetrance table output.

"Draft LaTeX review on sarcomere genetics in familial HCM."

Synthesis Agent → gap detection(Seidman 2001) → Writing Agent → latexEditText(structured review) → latexSyncCitations(Ackerman 2011, Elliott 2014) → latexCompile → PDF manuscript.

"Find GitHub code for HCM genetic simulation models."

Research Agent → paperExtractUrls(Thierfelder 1994) → Code Discovery → paperFindGithubRepo → githubRepoInspect → verified simulation scripts for myosin mutation modeling.

Automated Workflows

Deep Research workflow scans 50+ HCM genetics papers via citationGraph from Geisterfer-Lowrance (1990), producing structured reports on mutation prevalence. DeepScan's 7-step chain analyzes Richard et al. (2003) abstracts with CoVe checkpoints for testing guidelines. Theorizer generates hypotheses on modifiers from Seidman (2001) sarcomere data.

Frequently Asked Questions

What defines Hypertrophic Cardiomyopathy Genetics?

It examines sarcomere mutations, primarily β-cardiac myosin heavy chain missense variants, driving HCM left ventricular hypertrophy (Geisterfer-Lowrance et al., 1990).

What are key methods in HCM genetics?

Systematic gene screening of 10 sarcomere genes in cohorts (Richard et al., 2003); genetic testing per HRS/EHRA consensus (Ackerman et al., 2011).

What are major papers?

Geisterfer-Lowrance et al. (1990, 1376 citations) identified myosin mutations; Elliott et al. (2014, 4217 citations) provide ESC guidelines; Seidman and Seidman (2001, 1041 citations) outline cardiomyopathy genetics.

What open problems exist?

Unresolved incomplete penetrance and modifier effects in sarcomere mutations (Thierfelder et al., 1994); need better genotype-phenotype models (Marian and Braunwald, 2017).

Research Cardiomyopathy and Myosin Studies with AI

PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:

See how researchers in Health & Medicine use PapersFlow

Field-specific workflows, example queries, and use cases.

Health & Medicine Guide

Start Researching Hypertrophic Cardiomyopathy Genetics with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Medicine researchers